Polycyclo Ring System Having The Five-membered Hetero Ring As One Of The Cyclos Patents (Class 548/126)
  • Patent number: 11133474
    Abstract: Disubstituted diaryloxybenzoheterodiazole compound of general formula (1): in which:—Z represents a sulfur atom, an oxygen atom, a selenium atom; or an NR5 group in which R5 is selected from linear or branched C1-C20, preferably C1-C8, alkyl groups, or from optionally substituted aryl groups;—R1, R2 and R3 are as defined in the claims. The said disubstituted diaryloxybenzoheterodiazole compound of general formula (I) can advantageously be used as a spectrum converter in luminescent solar concentrators (LSCs) which are in turn capable of improving the performance of photovoltaic devices (or solar devices) selected, for example, from photovoltaic cells (or solar cells), photovoltaic modules (or solar modules) on either a rigid substrate or a flexible substrate.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: September 28, 2021
    Assignee: Eni S.P.A.
    Inventors: Luigi Abbondanza, Andrea Alessi, Antonio Alfonso Proto, Giuliana Schimperna, Liliana Gila
  • Patent number: 10954227
    Abstract: The present specification relates to a compound containing nitrogen, and a color conversion film, a backlight unit, and a display device, including the same.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: March 23, 2021
    Assignee: LG CHEM, LTD.
    Inventors: Seonkyoung Son, Milim Lee, Cheol Jun Song, Minju Kim, Hoyong Lee
  • Patent number: 10696690
    Abstract: The present invention provides compounds of Formula (I) used as Amyloid beta lowering agent for the treatment of neurodegenerative diseases.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: June 30, 2020
    Assignee: Ares Trading S.A.
    Inventors: Anna Quattropani, Dominique Swinnen
  • Patent number: 10364356
    Abstract: The present application relates to novel compounds and to devices which contain these compounds. The application also relates to a device for regulating the passage of energy from an outside space into an inside space, to a window containing the said device, and to uses of the said devices and compounds.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: July 30, 2019
    Assignee: Merck Patent GmbH
    Inventors: Peer Kirsch, Susann Gunst, Michael Junge, Andreas Beyer, Ursula Patwal
  • Patent number: 10077262
    Abstract: The present invention relates to new semiconducting compounds having at least one optionally substituted thienothiadiazole moiety. The compounds disclosed herein can exhibit high carrier mobility and/or efficient light absorption/emission characteristics, and can possess certain processing advantages such as solution-processability and/or good stability at ambient conditions.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: September 18, 2018
    Assignee: Flexterra, Inc.
    Inventors: Zhihua Chen, Antonio Facchetti
  • Patent number: 9932354
    Abstract: The present invention provides compounds of Formula (I) used as Amyloid beta lowering agent for the treatment of neurodegenerative diseases.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: April 3, 2018
    Assignee: Ares Trading S.A.
    Inventors: Anna Quattropani, Dominique Swinnen
  • Patent number: 9546999
    Abstract: The present invention relates to a method for detecting and optionally quantifying at least one molecule comprising at least one protonated group such as an amine function immobilized at the surface of the solid substrate, said method being a reversible, direct and colorimetric method that uses a coloring agent. The present invention also relates to various uses of said method and the solutions used during said method.
    Type: Grant
    Filed: March 5, 2009
    Date of Patent: January 17, 2017
    Assignee: 1/ CENTRE NATIONAL D'ETUDES SPATIALES
    Inventors: Gaëlle Coussot, Odile Vandenabeele-Trambouze, Isabelle Desvignes, Michel Dobrijevic, Aurélie Le Postollec, Pascale Chazalnoel
  • Patent number: 9167819
    Abstract: The invention relates to suifin- and sulfonimidoylbenzamides of general formula (S) used as herbizides. In said formula (I), R, R?, R?, X, W and Z represent radicals such as hydrogen, organic radicals such as alkyl, and other radicals such as halogens. Q represents a tetrazolyl-, triazolyl or oxadiazolyl radicals.
    Type: Grant
    Filed: February 18, 2013
    Date of Patent: October 27, 2015
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Hartmut Ahrens, Ralf Braun, Simon Doerner-Rieping, Arnim Koehn, Stefan Lehr, Hansjoerg Dietrich, Dirk Schmutzler, Elmar Gatzweiler, Christopher Hugh Rosinger
  • Patent number: 9171676
    Abstract: The present invention relates to an organic colorant corresponding to one of the following structures (I) or (II): eD-pi-conjugated chromophore-L-A??(I) A-L-pi-conjugated chromophore-eD??(II) in which eD represents an electron donor segment; L represents a covalent bond or a spacer segment; A represents an electron attractor segment able to form a covalent bond with a semi-conductor; the pi-conjugated chromophore comprising at least two aromatic rings, at least one of which is a thiophene, selenophene or furan type ring. The present invention relates to the use thereof as photosensitizer in a photovoltaic device and said photovoltaic device.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: October 27, 2015
    Assignee: COMMISSARIAT {dot over (A)} L'ĖNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES
    Inventors: Renaud Demadrille, Yann Kervella
  • Patent number: 9073851
    Abstract: Provided herein are methods and compositions inter alia for treating diseases, including hyperproliferative diseases, migraine headaches, and depression.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: July 7, 2015
    Assignee: Board of Regents, the University of Texas System
    Inventors: Bulent Ozpolat, Gabriel Lopez-Berestein, Kevin N. Dalby, Jiney Jose
  • Patent number: 9040498
    Abstract: The present invention relates to novel 1,2,3-triazolyl purine derivatives. The invention also relates to using the derivatives to treat cancer and various viral infections.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: May 26, 2015
    Assignee: Research Foundation of the City University of New York
    Inventor: Mahesh K. Lakshman
  • Patent number: 9035067
    Abstract: N-(1,2,5-Oxadiazol-3-yl)-, N-(tetrazol-5-yl)- and N-(triazol-5-yl)bicycloarylcarboxamides of the general formula (I) are described as herbicides. In this formula (I), R3, R4 and R5 are each radicals such as hydrogen, organic radicals such as alkyl, and other radicals such as halogen. Q is a heterocycle. X and Y are each oxygen and sulfur.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: May 19, 2015
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Andreas Almsick, Hartmut Ahrens, Arnim Köhn, Simon Dörner-Rieping, Ralf Braun, Isolde Häuser-Hahn, Christopher Hugh Rosinger, Ines Heinemann, Elmar Gatzweiler
  • Publication number: 20150133446
    Abstract: The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.
    Type: Application
    Filed: April 24, 2013
    Publication date: May 14, 2015
    Inventors: R. Michael Lawrence, Michael M. Miller, Dietmar Alfred Seiffert, Shoshana L. Posy, Pancras C. Wong, Jacques Banville, Edward H. Ruediger, Daniel H. Deon, Alain Martel, François Tremblay, Julia Guy, Jean-François Lavallée, Marc Gagnon
  • Publication number: 20150119390
    Abstract: The present invention provides imidazothiadiazole compounds of Formula (I); Wherein W, Y, R0, R2, R4, Ra, Rb, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Application
    Filed: April 24, 2013
    Publication date: April 30, 2015
    Inventors: Alain Martel, François Tremblay, Anne Marinier, Eldon Scott Priestley, Shoshana L. Posy, R. Michael Lawrence, Michael M. Miller
  • Publication number: 20150108409
    Abstract: The invention relates to compounds based on benzo[1,2-b:4,5-b?]dithiophene (BDT), methods for their preparation and intermediates used therein, mixtures and formulations containing them, the use of the compounds, mixtures and formulations as semiconductor in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices, and to OE devices comprising these compounds, mixtures or formulations.
    Type: Application
    Filed: May 6, 2013
    Publication date: April 23, 2015
    Applicant: Merck Patent GmbH
    Inventors: Frank Egon Meyer, Nicolas Blouin, Toby Cull, William Mitchell
  • Publication number: 20150112081
    Abstract: A naphthobisthiadiazole derivative is represented by Formula 1. In Formula 1, Z is selected from a hydrogen atom, a boronic acid group, a boronic acid ester group, a trifluoroborate salt group and a triolborate salt group, and at least one Z is a boronic acid group, a boronic acid ester group, a trifluoroborate salt group or a triolborate salt group. The naphthobisthiadiazole derivative is an organoboron compound, and can be converted to various compounds by a Suzuki-Miyaura coupling reaction; thus, is applicable as a precursor of complex compounds. Using the naphthobisthiadiazole derivative, research, development, and practical applications of low molecular weight compounds and high-molecular compounds useful for various organic semiconductor materials and the like can be ensured.
    Type: Application
    Filed: February 27, 2013
    Publication date: April 23, 2015
    Inventors: Kazuo Takimiya, Itaru Osaka, Kazuaki Kawashima
  • Publication number: 20150099800
    Abstract: The invention provides for novel lipase inhibitors, and compositions and devices comprising the same. The invention further provides for methods for treatment of disorders comprising administration of novel diacylglycerol lipase inhibitors, and compositions and devices comprising said inhibitors. In some embodiments, the disorders are pancreatitis, obesity, shock or pancreatic necrosis. The invention further provides for novel ether lipid reporter compounds and methods of assaying enzymatic activity comprising contacting a compound with a novel ether lipid reporter compound.
    Type: Application
    Filed: May 24, 2013
    Publication date: April 9, 2015
    Inventor: Richard I. Duclos, JR.
  • Publication number: 20150094297
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Application
    Filed: April 24, 2013
    Publication date: April 2, 2015
    Inventors: Jacques Banville, Roger Rèmillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dubé, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • Patent number: 8981113
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R0, R1, R2, R3, R4 and a are defined herein.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: March 17, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark J Macielag, Mingde Xia, Xiaoqing Xu
  • Patent number: 8980929
    Abstract: The present invention is directed to novel amino-substituted seven-membered heterocyclic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: March 17, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jacqueline D. Hicks, Tesfaye Biftu, Ping Chen, Xiaoxia Qian, Robert R. Wilkening
  • Publication number: 20150059853
    Abstract: A benzobis(thiadiazole) derivative represented by the formula (1): in which R represents a group containing at least one fluorine atom (with the proviso that fluorine atom (F) and trifluoromethyl group (—CF3) are excluded), and m represents an integer of from 1 to 10.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 5, 2015
    Inventors: Shizuo Tokito, Daisuke Kumaki, Hidetaka Shima, Hiroyuki Oda, Yasuhiro Tanaka, Kazuaki Kakita, Toshikazu Machida, Yasuhiro Yoneda, Youji Omata, Tetsuro Shimano
  • Patent number: 8957218
    Abstract: The present invention relates to 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: February 17, 2015
    Assignee: UCB Pharma S.A.
    Inventors: Laurent Provins, Yannick Quesnel
  • Patent number: 8937087
    Abstract: [Problem] A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. [Means for Solution] The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: January 20, 2015
    Assignee: Astellas Pharma Inc.
    Inventors: Ryota Shiraki, Takahiko Tobe, Shimpei Kawakami, Hiroyuki Moritomo, Makoto Ohmiya
  • Patent number: 8927734
    Abstract: A batch reactor process for the synthesis of potassium 5,7-dinitro-[2,1,3]-benzoxadiazol-4-olate-3-oxide (KDNP) from 3-bromo-2,4,6-trinitroanisole (ETNA) includes adding BTNA to a reaction vessel containing potassium azide (KN3) and water (H2O). The resulting mixture is heated to 90° C. followed by cooling to room temperature and agitating the final solution. The precipitate KDNP product is recovered by filtration.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: January 6, 2015
    Assignee: The United States of America as Represented by the Secretary of the Navy
    Inventors: Patrick Caruana, Bradley Sleadd, John Fronabarger, Michael D. Williams
  • Publication number: 20140371278
    Abstract: Disclosed are compound of formula (I) and pharmaceutically accepted salts and prodrugs thereof, wherein each of R1, R2, R3, R4, R5, R6, X1 and X2 is as defined in the description. These compounds are protein kinases inhibitors, especially the inhibitors of Mek, which are useful in the treatment of cancers and inflammation of mammals. Disclosed are the treatment methods of cancers and inflammation of mammals as well as pharmaceutical compositions comprising the compounds described herein. The preparation of benzoheterocyclic compounds are disclosed. Disclosed are the preparation of potential drug candidates, such as benzooxazol, benzothiazol, benzothiadiazol and the like.
    Type: Application
    Filed: January 16, 2013
    Publication date: December 18, 2014
    Applicant: TIANJIN BINJIANG PHARMA, INC.
    Inventors: Hongqi Tian, Conghui Ji, Chunlei Liu, Li Kong, Ying Cheng, Gongchao Huang
  • Publication number: 20140371463
    Abstract: Compound comprising a benzoetherodiazole group of formula (I) and at least one benzodithiophene group or a mixture of compounds comprising a benzoetherodiazole group and at least one benzodithiophene group of formulae (II) and (III). Both said compound and said mixture of compounds can be advantageously used as spectrum converters in luminescent solar concentrators (LSCs), capable, in their turn, of enhancing the performances of solar devices (i.e. devices for exploiting solar energy) such as, for example, photovoltaic cells, photoelectrolytic cells.
    Type: Application
    Filed: December 20, 2012
    Publication date: December 18, 2014
    Inventors: Roberto Fusco, Paolo Biagini, Stefano Maiorana, Emanuela Licandro
  • Patent number: 8901298
    Abstract: The present invention relates to condensed aromatic compounds with multiple ring bridging of the general formulae (1), (2), (3), (4) and (5). The invention furthermore relates to the use of the compounds according to the invention in an organic electronic device and to a process for the preparation of the compounds according to the invention. The invention furthermore relates to an electronic device which comprises the compounds according to the invention.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: December 2, 2014
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Christof Pflumm, Holger Heil, Arne Buesing
  • Publication number: 20140341776
    Abstract: Thiophene containing water-soluble oligomers were synthesized and characterized. The photophysical properties of these compounds were studied; transient absorption spectroscopy was used to probe the triplet excited state and their ability to sensitize singlet oxygen was spectroscopically monitored in deuterated methanol. The above compounds were tested for their light activated biocidal properties against S. aureus both under UV and visible radiation. Among the oligomers studied, the terthiophene derivative was found to kill the bacteria efficiently.
    Type: Application
    Filed: July 5, 2012
    Publication date: November 20, 2014
    Applicants: STC.UNM, University of Florida Reearch Foundation, Inc.
    Inventors: Kirk S. Schanze, Anand Parthasarathy, Subhadip Goswami, David G. Witten, Eunkyung Ji, Thomas S. Corbitt, Dimitri Dascier
  • Publication number: 20140343066
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.
    Type: Application
    Filed: December 20, 2013
    Publication date: November 20, 2014
    Inventors: Irini Akritopoulou-Zanze, Brian D. Wakefield, Helmut Mack, Sean C. Turner, Alan F. Gasiecki, Vijaya J. Gracias, Kathy A. Sarris, Douglas M. Kalvin, Melissa J. Michmerhuizen, Qi Shuai, Jyoti R. Patel, Margaretha H.M. Bakker, Nicole Teusch, Eric F. Johnson, Peter J. Kovar, Stevan W. Djuric, Andrew J. Long, Anil Vasudevan, Dawn M. George, Lu Wang, Biqin Li, Nigel S. Moore, Adrian D. Hobson, Keith W. Woods, Julie M. Miyashiro, Steven L. Swann, Jr., Thomas D. Penning
  • Patent number: 8883954
    Abstract: A photovoltaic cell is provided that includes a first electrode, a second electrode, and a photoactive layer disposed between the first and second electrodes. The photoactive layer includes a photoactive polymer containing a first monomer repeat unit, which contains a moiety of formula (1): in which A and R are defined in the specification.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: November 11, 2014
    Assignee: Merck Patent GmbH
    Inventors: Paul Byrne, Li Wen, David P. Waller, Taizoon Canteenwala, Patrick Foyle, Edward Jackson
  • Publication number: 20140329266
    Abstract: A measure for selective fluorescent labeling of the Golgi apparatus, which has low cytotoxicity and excellent intracellular stability, is provided. According to the present invention, provided are a ceramide derivative represented by the following Chemical formula 1: in the formula, R1 is an alkyl group having 1 to 12 carbon atoms, R2 is an alkyl group having 1 to 20 carbon atoms, and n is an integer of 1 to 20, and a Golgi apparatus-labeling fluorescent probe using the same.
    Type: Application
    Filed: August 13, 2012
    Publication date: November 6, 2014
    Applicant: National University Corporation Chiba University
    Inventors: Atsushi Nishida, Hiroyuki Nakamura, Tomohiko Makiyama, Toshihiko Murayama
  • Patent number: 8877748
    Abstract: A heterocyclic fused anthraquinone derivative, which is represented by a formula (I): wherein R1 is a substituent being one selected from a group consisting of hydrogen, halogens, aminoalkyl group, sulfoalkyl group, haloalkyl group, piperazino group, sulfonyl group, morpholino group, alkali group or one substituent represented by a formula (II): wherein R2 is amino group, oxyl group or a thiol group. In the meantime, a method for manufacturing the above-mentioned heterocyclic fused anthraquinone derivatives and a pharmaceutical composition using thereof are also disclosed here.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: November 4, 2014
    Assignee: National Defense Medical Center
    Inventors: Hsu-Shan Huang, Yu-Ru Lee, Tsung-Chih Chen
  • Patent number: 8865130
    Abstract: The presently disclosed subject matter provides compositions that selectively bind cyclooxygenase-2 and comprise a therapeutic and/or diagnostic moiety. Also provided are methods for using the disclosed compositions for diagnosing (i.e., by imaging) a target cell and/or treating a disorder associated with a cyclooxygenase-2 biological activity.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: October 21, 2014
    Assignee: Vanderbilt University
    Inventors: Lawrence J. Marnett, Md. Jashim Uddin, Brenda C. Crews
  • Publication number: 20140309431
    Abstract: Disubstituted naphthoheterodiazole compound having general formula (I): wherein: Z represents a heteroatom selected from oxygen (O), sulfur (S), selenium (Se), tellurium (Te), preferably sulfur (S); R1, R2, R3, R4, R5, R6 and R7, equal to or different from each other, represent a hydrogen atom; or they are selected from n-butyl, iso-butyl, sec-butyl, t-butyl. Said disubstituted naphthoheterodiazole compound having general formula (I) can be advantageously used as spectrum converter in luminescent solar concentrators (LSCs), in its turn capable of improving the performances of photovoltaic devices (or solar devices) selected, for example, from photovoltaic cells (or solar cells), photovoltaic modules (or solar modules), on both rigid and flexible supports.
    Type: Application
    Filed: April 11, 2014
    Publication date: October 16, 2014
    Applicant: ENI S.p.A.
    Inventors: Andrea ALESSI, Samuele Santarelli
  • Publication number: 20140309430
    Abstract: Process for the preparation of a benzoheterodiazole compound disubstituted with benzodithiophene groups which comprises reacting at least one disubstituted benzoheterodiazole compound with at least one monostannylated benzodithiophene compound. Said benzoheterodiazole compound disubstituted with benzodithiophene groups can be advantageously used in the construction of luminescent solar concentrators (LSCs). Furthermore, said benzoheterodiazole compound disubstituted with benzodithiophene groups can be advantageously used in the construction of photovoltaic devices (or solar devices) such as, for example, photovoltaic cells (or solar cells), photovoltaic modules (or solar modules), on both rigid and flexible supports. Furthermore, said benzoheterodiazole compound disubstituted with benzodithiophene groups can be advantageously used as precursor of monomeric units in the preparation of semiconductor polymers.
    Type: Application
    Filed: April 11, 2014
    Publication date: October 16, 2014
    Applicant: ENI S.p.A.
    Inventors: Samuele SANTARELLI, Gabriele BIANCHI
  • Patent number: 8859592
    Abstract: A compound of formula (I): wherein A1, A2, A3, A4, A5, G1, R1, R2, R3 and R4 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, nematicidal and molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode and mollusc pests.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: October 14, 2014
    Assignee: Syngenta Corp Protection LLC
    Inventors: Peter Renold, Jerome Yves Cassayre, Jagadish Pabba, Myriem El Qacemi, Thomas Pitterna
  • Publication number: 20140290748
    Abstract: The present invention relates to an organic colorant corresponding to one of the following structures (I) or (II): eD-pi-conjugated chromophore-L-A??(I) A-L-pi-conjugated chromophore-eD??(II) in which eD represents an electron donor segment; L represents a covalent bond or a spacer segment; A represents an electron attractor segment able to form a covalent bond with a semi-conductor; the pi-conjugated chromophore comprising at least two aromatic rings, at least one of which is a thiophene, selenophene or furan type ring. The present invention relates to the use thereof as photosensitizer in a photovoltaic device and said photovoltaic device.
    Type: Application
    Filed: November 12, 2012
    Publication date: October 2, 2014
    Applicant: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Renaud Demadrille, Yann Kervella
  • Publication number: 20140296307
    Abstract: The present invention relates compounds and compositions for interfering with the association of Myc and Max. These compounds and compositions are useful in methods for inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell comprise contacting the cell with an amount of a compound that interferes with Myc and Max association effective to inhibit growth or proliferation of the cell. The compounds exhibit increased inhibitory activity against c-Myc relative to the known c-Myc inhibitor small-molecule benzofurazan N-([1,1?-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine (10074-G5).
    Type: Application
    Filed: March 27, 2014
    Publication date: October 2, 2014
    Applicant: University of Maryland, Baltimore
    Inventor: STEVEN FLETCHER
  • Publication number: 20140296308
    Abstract: The present invention relates to compounds with a benzoxadiazolyl amine structure which are capable of inhibiting the activation or the biological activity of p38 mitogen-activated protein kinase (MAPK) and the use thereof in the treatment of a disease that can be alleviated by means of inhibiting the activation or the biological activity of said p38 MAPK, for example, an inflammatory disease or a disease presenting with pain.
    Type: Application
    Filed: October 31, 2012
    Publication date: October 2, 2014
    Inventors: Federico Mayor Ménendez, Cristina Murga Montesinos, Pedro Manuel Campos Muelas, Jacoba Johana Heijnen, Anna Maria Agnes Antonius Kavelaars, Antonio Morreale de León, Rubén Gil Redondo
  • Patent number: 8846942
    Abstract: Luminescent solar concentrator (LSC) includes at least one disubstituted benzothiadiazole compound having general formula (I):
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: September 30, 2014
    Assignee: Eni S.p.A.
    Inventors: Samuele Santarelli, Roberto Fusco, Gabriele Bianchi
  • Patent number: 8846726
    Abstract: The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: September 30, 2014
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Eddy W. Yue
  • Publication number: 20140275093
    Abstract: This invention provides compounds of formula (I): wherein ring A, X1, X2, X3, R2, R4b, R10, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    Type: Application
    Filed: October 16, 2013
    Publication date: September 18, 2014
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Kenneth M. Gigstad, Sean J. Harrison, He Xu
  • Publication number: 20140252278
    Abstract: Disclosed is a p-type organic semiconductive material that is easy to produce and that has a high planarity in its polymer skeleton, and also provides a photoelectric conversion material, a photoelectric conversion layer, a photoelectric conversion element, and an organic thin film solar cell each having high photoelectric conversion efficiency and using the p-type organic semiconductive material. Specifically, the invention provides a bibenzo[b]furan compound having at least one constitutional unit represented by the following formula (1) or (2), as well as a photoelectric conversion material, a photoelectric conversion layer, a photoelectric conversion element, and an organic thin film solar cell each using that compound for a p-type organic semiconductive material.
    Type: Application
    Filed: October 22, 2012
    Publication date: September 11, 2014
    Applicant: Adeka Corporation
    Inventors: Mineki Hasegawa, Toru Yano, Ryo Taniuchi
  • Patent number: 8822467
    Abstract: The present invention provides biaryl oxyacetic acid compounds which may be useful for treating inflammatory disorders, including disorders affecting the respiratory system and skin.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: September 2, 2014
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Brian F. McGuinness, Koc-Kan Ho, Suresh Babu, Guizhen Dong, Jingqi Duo, Thuy X. H. Le, Kurt W. Saionz
  • Patent number: 8822508
    Abstract: The present invention relates to 2-oxo-1-pyrrolidine imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: September 2, 2014
    Assignee: UCB Pharma, S.A.
    Inventors: Yannick Quesnel, Laurent Turet, Joël Mercier
  • Publication number: 20140243334
    Abstract: This invention provides compounds of formula (I): wherein R1a, R1b, R1c, R2a, R2b, R2c, and R2d have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    Type: Application
    Filed: May 5, 2014
    Publication date: August 28, 2014
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Emily F. Calderwood, Dylan B. England, Alexandra E. Gould, Sean J. Harrison, Liting Ma
  • Publication number: 20140243366
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.
    Type: Application
    Filed: May 1, 2014
    Publication date: August 28, 2014
    Applicant: CalciMedica, Inc.
    Inventors: Jeffrey P. WHITTEN, Yazhong Pei, Jianguo Cao, Zhijun Wang, Evan Rogers, Brian Dyck, Jonathan Grey
  • Patent number: 8802975
    Abstract: Provided are compounds with a donor moiety, a first acceptor moiety and a second acceptor moiety, as shown by Formula (I): With the unique molecular design, compounds of Formula (I) can provide a desirable power conversion efficiency. Moreover, this invention also provides organic thin-film solar cells comprising the above-mentioned compounds.
    Type: Grant
    Filed: January 3, 2012
    Date of Patent: August 12, 2014
    Inventors: Ken-Tsung Wong, Hao-Wu Lin, Li-Yen Lin, Francis Lin, Yi-Hong Chen, Shi-Wen Chiu
  • Publication number: 20140221663
    Abstract: Process for the preparation of a benzohetero[1,3]diazole compound disubstituted with heteroaryl groups which comprises reacting at least one benzohetero[1,3]diazole compound disubstituted with at least one heteroaryl compound. Said benzohetero[1,3]diazole compound disubstituted with heteroaryl groups can be advantageously used in the construction of luminescent solar concentrators (LSC). Furthermore, said benzohetero[1,3]diazole compound disubstituted with heteroaryl groups can be advantageously used in the construction of photovoltaic devices such as, for example, photovoltaic cells, photovoltaic modules, solar cells, solar modules, on both a rigid and flexible support. Said benzohetero[1,3]diazole compound disubstituted with heteroaryl groups can also be advantageously used as a precursor of monomeric units in the preparation of semiconductor polymers.
    Type: Application
    Filed: August 1, 2012
    Publication date: August 7, 2014
    Applicant: Eni S.P.A.
    Inventors: Giuliana Schimperna, Gabriele Bianchi
  • Patent number: 8772321
    Abstract: Methods and pharmaceutical compositions for treating cancer utilizing compounds characterized by the following structure: and their pharmaceutically acceptable salts.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: July 8, 2014
    Assignee: National Defense Medical Center
    Inventors: Hsu-Shan Huang, Tsung-Chih Chen, Tai-Lung Cha